Skip to main content

Aubagio FDA Approval History

FDA Approved: Yes (First approved September 12, 2012)
Brand name: Aubagio
Generic name: teriflunomide
Dosage form: Tablets
Company: Sanofi
Treatment for: Multiple Sclerosis

Aubagio (teriflunomide) is an oral pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Development timeline for Aubagio

DateArticle
Sep 12, 2012Approval FDA Approves New Multiple Sclerosis Treatment Aubagio
Oct 20, 2011Oral Therapy Teriflunomide (Aubagio) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis

See also

Aubagio (teriflunomide) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer